LDN Website Update, November 2003

[Guest guest]

LDN Website Update

www.low dose naltrexone.org / www.ldninfo.org

Latest News for November 2003 has been posted on the website, as

follows:

* A Clinical Trial Starts.

At long last, an independent clinical trial of low dose naltrexone is

beginning at a medical center in the US. This represents an important

recognition of the therapeutic potential of LDN. Once the trial is

completed and successful, its publication should do much to persuade

the medical world of the value of LDN. The study is being done on

Crohn's disease, a prevalent autoimmune disease, at Penn State Hershey

Medical Center. The study website is:

http://www.hmc.psu.edu/colorectal/research/naltrexone.htm

* Alzheimer's Disease.

Dr. Bihari reports that he currently has three patients who have

Alzheimer's disease. Since starting LDN, none of them has shown

further progression, which is usually inexorable in this disorder. The

initial such patient came to him four years ago to seek treatment for

prevention of recurrence of colon cancer. The second patient saw

Bihari some two-and-one-half years ago for treatment of non-Hodgkin's

lymphoma, and the third began LDN two years ago for an autoimmune

problem. Before their first visits, each of the three had been

diagnosed with moderately severe Alzheimer's disease by a neurologist.

* HIV/AIDS.

Dr. Bihari describes a " natural experiment " unintentionally performed

by one of his patients, a 42-year-old man with HIV disease who lives

in Florida and whose standard medications (Kaletra, Viramune) are paid

for by a governmental program. When he lost his job in May 2003 (six

months ago) he decided to stop LDN in order to save money. At that

time, his CD4 cell count was 950 and the CD4% was 38%. Lab tests two

and one-half months later showed that the CD4 count had dropped to 590

and the CD4% was down to 31%. Three months ago, on regaining

employment, he restarted his LDN — and repeat tests two weeks ago

showed the CD4 count had climbed back to 968 and the CD4% had returned

to 38%. Viral load had remained undetectable throughout this time.

This is felt to be a good demonstration of the efficacy of LDN as a

supplement to standard HIV drugs.

LDN Website Editors

email@...

[Guest guest]

Exciting stuff, THX :0)